A phase 2 trial of trastuzumab deruxtecan (T-DXd, DS-8201) in patients with HER2-positive, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma

被引：0
|
作者：
Fuchs, C. [1 ]
Shahidi, J. [2 ]
Mathew, L. [2 ]
Qin, A. [2 ]
Van Cutsem, E. [3 ,4 ]
机构：
[1] Yale Canc Ctr, Smilow Canc Hosp, New Haven, CT USA
[2] Daiichi Sankyo Inc, Basking Ridge, NJ USA
[3] Univ Hosp Gasthuisberg Leuven, Leuven, Belgium
[4] Katholieke Univ Leuven, Leuven, Belgium
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.04.266
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-184
引用
收藏
页码：S150 / S150
页数：1
相关论文
共 50 条
  • [1] A phase II trial of [fam-] trastuzumab deruxtecan (T-DXd, DS-8201a) in subjects with HER2-positive, unresectable, or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
    Fuchs, Charles S.
    Shahidi, Javad
    Mathew, Lijoy
    Qin, Amy
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [2] Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma: A randomized, phase 2, multicenter, open-label study (DESTINY-Gastric01)
    Yamaguchi, K.
    Bang, Y.
    Iwasa, S.
    Sugimoto, N.
    Ryu, M.
    Sakai, D.
    Chung, H.
    Kawakami, H.
    Yabusaki, H.
    Lee, J.
    Saito, K.
    Kawaguchi, Y.
    Kamio, T.
    Kojima, A.
    Sugihara, M.
    Shitara, K.
    ANNALS OF ONCOLOGY, 2020, 31 : S235 - S235
  • [3] Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized, phase II, multicenter, open-label study (DESTINY-Gastric01).
    Shitara, Kohei
    Bang, Yung-Jue
    Iwasa, Satoru
    Sugimoto, Naotoshi
    Ryu, Min-hee
    Sakai, Daisuke
    Chung, Hyun Cheol
    Kawakami, Hisato
    Yabusaki, Hiroshi
    Lee, Jeeyun
    Saito, Kaku
    Kawaguchi, Yoshinori
    Kamio, Takahiro
    Kojima, Akihito
    Sugihara, Masahiro
    Yamaguchi, Kensei
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01).
    Yamaguchi, Kensei
    Bang, Yung-Jue
    Iwasa, Satoru
    Sugimoto, Naotoshi
    Ryu, Min-Hee
    Sakai, Daisuke
    Chung, Hyun Cheol Cheol
    Kawakami, Hisato
    Yabusaki, Hiroshi
    Lee, Jeeyun
    Saito, Kaku
    Kawaguchi, Yoshinori
    Kamio, Takahiro
    Kojima, Akihito
    Sugihara, Masahiro
    Shitara, Kohei
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [5] Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01)
    Yamaguchi, Kensei
    Bang, Yung-Jue
    Iwasa, Satoru
    Sugimoto, Naotoshi
    Ryu, Min-Hee
    Sakai, Daisuke
    Chung, Hyun Cheol Cheol
    Kawakami, Hisato
    Yabusaki, Hiroshi
    Lee, Jeeyun
    Saito, Kaku
    Kawaguchi, Yoshinori
    Kamio, Takahiro
    Kojima, Akihito
    Sugihara, Masahiro
    Shitara, Kohei
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [6] Trastuzumab deruxtecan (T-DXd, DS-8201) in HER2-positive metastatic breast cancer previously treated with T-DM1: DESTINY-Breast01 Study
    Krop, I.
    Saura Manich, C.
    Yamashita, T.
    Park, Y. H.
    Kim, S. -B. K.
    Tamura, K.
    Andre, F.
    Iwata, H.
    Ito, Y.
    Tsurutani, J.
    Sohn, J.
    Denduluri, N.
    Perrin, C.
    Aogi, K.
    Tokunaga, E.
    Im, S. -A.
    Lee, K. S.
    Hurvitz, S.
    Cortes, J.
    Lee, C.
    Chen, S.
    Zhang, L.
    Shahidi, J.
    Yver, A.
    Modi, S.
    SWISS MEDICAL WEEKLY, 2020, : 25S - 25S
  • [7] Spotlight on Trastuzumab Deruxtecan (DS-8201, T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer
    Azar, Ibrahim
    Alkassis, Samer
    Fukui, Jami
    Alsawah, Fares
    Fedak, Kalub
    Al Hallak, Mohammed Najeeb
    Sukari, Ammar
    Nagasaka, Misako
    LUNG CANCER-TARGETS AND THERAPY, 2021, 12 : 103 - 114
  • [8] Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-low, advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Results of the exploratory cohorts in the phase II, multicenter, open-label DESTINY-Gastric01 study
    Yamaguchi, K.
    Bang, Y-J.
    Iwasa, S.
    Sugimoto, N.
    Ryu, M-H.
    Sakai, D.
    Chung, H. C.
    Kawakami, H.
    Yabusaki, H.
    Lee, J.
    Saito, K.
    Kawaguchi, Y.
    Kamio, T.
    Kojima, A.
    Sugihara, M.
    Shitara, K.
    ANNALS OF ONCOLOGY, 2020, 31 : S899 - S900
  • [9] Multicenter phase II study of trastuzumab deruxtecan (DS-8201) for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial.
    Ohba, Akihiro
    Morizane, Chigusa
    Ueno, Makoto
    Kobayashi, Satoshi
    Kawamoto, Yasuyuki
    Komatsu, Yoshito
    Ikeda, Masafumi
    Sasaki, Mitsuhito
    Okano, Naohiro
    Furuse, Junji
    Hiraoka, Nobuyoshi
    Yoshida, Hiroshi
    Kuchiba, Aya
    Ogawa, Gakuto
    Nakamura, Kenichi
    Matsui, Naoko
    Nakamura, Yoshiaki
    Okamoto, Wataru
    Yoshino, Takayuki
    Okusaka, Takuji
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [10] Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): An investigator-initiated multicenter phase 2 study (HERB trial).
    Ohba, Akihiro
    Morizane, Chigusa
    Kawamoto, Yasuyuki
    Komatsu, Yoshito
    Ueno, Makoto
    Kobayashi, Satoshi
    Ikeda, Masafumi
    Sasaki, Mitsuhito
    Furuse, Junji
    Okano, Naohiro
    Hiraoka, Nobuyoshi
    Yoshida, Hiroshi
    Kuchiba, Aya
    Sadachi, Ryo
    Nakamura, Kenichi
    Matsui, Naoko
    Nakamura, Yoshiaki
    Okamoto, Wataru
    Yoshino, Takayuki
    Okusaka, Takuji
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345